Patents by Inventor Joseph Chung Tak Wong
Joseph Chung Tak Wong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11707509Abstract: A pharmaceutically acceptable insulin premix formulation contains about 0.1-10.0 Unit/mL of insulin for intravenous administration and preferably further contains a tonicity adjuster. The methods for making and using such formulation are also provided. The pharmaceutically acceptable insulin premix formulation may be aseptically filled into a flexible container assembly to form a pharmaceutical insulin premix product. The insulin premix product can be a sterile and ready-to-use aqueous solution for glycemic control in an individual with metabolic disorders through intravenous infusion. The insulin premix product is unexpectedly stable when freshly prepared and also during its shelf-life of storage at refrigeration temperatures of 2° C. to 5° C. for 24 months followed by additional 30 days at room temperatures of 23° C. to 27° C., even without any added preservative, any added zinc, any added surfactant or any other added stabilizing excipient.Type: GrantFiled: April 16, 2021Date of Patent: July 25, 2023Assignees: Baxter International, Inc., Baxter Healthcare SAInventors: Joseph Chung Tak Wong, Sarah Elizabeth Lee
-
Publication number: 20210315976Abstract: A pharmaceutically acceptable insulin premix formulation contains about 0.1-10.0 Unit/mL of insulin for intravenous administration and preferably further contains a tonicity adjuster. The methods for making and using such formulation are also provided. The pharmaceutically acceptable insulin premix formulation may be aseptically filled into a flexible container assembly to form a pharmaceutical insulin premix product. The insulin premix product can be a sterile and ready-to-use aqueous solution for glycemic control in an individual with metabolic disorders through intravenous infusion. The insulin premix product is unexpectedly stable when freshly prepared and also during its shelf-life of storage at refrigeration temperatures of 2° C. to 5° C. for 24 months followed by additional 30 days at room temperatures of 23° C. to 27° C., even without any added preservative, any added zinc, any added surfactant or any other added stabilizing excipient.Type: ApplicationFiled: April 16, 2021Publication date: October 14, 2021Inventors: Joseph Chung Tak Wong, Sarah Elizabeth Lee
-
Patent number: 11033608Abstract: A pharmaceutically acceptable insulin premix formulation contains about 0.1-10.0 Unit/mL of insulin for intravenous administration and preferably further contains a tonicity adjuster. The methods for making and using such formulation are also provided. The pharmaceutically acceptable insulin premix formulation may be aseptically filled into a flexible container assembly to form a pharmaceutical insulin premix product. The insulin premix product can be a sterile and ready-to-use aqueous solution for glycemic control in an individual with metabolic disorders through intravenous infusion. The insulin premix product is unexpectedly stable when freshly prepared and also during its shelf-life of storage at refrigeration temperatures of 2° C. to 5° C. for 24 months followed by additional 30 days at room temperatures of 23° C. to 27° C., even without any added preservative, any added zinc, any added surfactant or any other added stabilizing excipient.Type: GrantFiled: October 8, 2020Date of Patent: June 15, 2021Assignees: Baxter International, Inc., Baxter Healthcare SAInventors: Joseph Chung Tak Wong, Sarah Elizabeth Lee
-
Publication number: 20210052704Abstract: A pharmaceutically acceptable insulin premix formulation contains about 0.1-10.0 Unit/mL of insulin for intravenous administration and preferably further contains a tonicity adjuster. The methods for making and using such formulation are also provided. The pharmaceutically acceptable insulin premix formulation may be aseptically filled into a flexible container assembly to form a pharmaceutical insulin premix product. The insulin premix product can be a sterile and ready-to-use aqueous solution for glycemic control in an individual with metabolic disorders through intravenous infusion. The insulin premix product is unexpectedly stable when freshly prepared and also during its shelf-life of storage at refrigeration temperatures of 2° C. to 5° C. for 24 months followed by additional 30 days at room temperatures of 23° C. to 27° C., even without any added preservative, any added zinc, any added surfactant or any other added stabilizing excipient.Type: ApplicationFiled: October 8, 2020Publication date: February 25, 2021Inventors: Joseph Chung Tak Wong, Sarah Elizabeth Lee
-
Patent number: 10799564Abstract: A pharmaceutically acceptable insulin premix formulation contains about 0.1-10.0 Unit/mL of insulin for intravenous administration and preferably further contains a tonicity adjuster. The methods for making and using such formulation are also provided. The pharmaceutically acceptable insulin premix formulation may be aseptically filled into a flexible container assembly to form a pharmaceutical insulin premix product. The insulin premix product can be a sterile and ready-to-use aqueous solution for glycemic control in an individual with metabolic disorders through intravenous infusion. The insulin premix product is unexpectedly stable when freshly prepared and also during its shelf-life of storage at refrigeration temperatures of 2° C. to 5° C. for 24 months followed by additional 30 days at room temperatures of 23° C. to 27° C., even without any added preservative, any added zinc, any added surfactant or any other added stabilizing excipient.Type: GrantFiled: November 12, 2019Date of Patent: October 13, 2020Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Joseph Chung Tak Wong, Sarah Elizabeth Lee
-
Publication number: 20120207762Abstract: Stable pharmaceutical formulations and methods of making same are provided. In a general embodiment, the present disclosure provides a method of making a stable pharmaceutical formulation comprising adding one or more vitrifying additives to an aqueous pharmaceutical solution to raise the glass transition temperature of the aqueous pharmaceutical solution. The aqueous pharmaceutical solution can be cooled to a temperature of about ?50° C. to about ?10° C. The vitrifying additive enhances the formation of a glass or amorphous solid of the aqueous pharmaceutical solution at cryogenic temperatures (?50 to ?10° C.), and the pharmaceutical formulation can be thawed to liquid form and administered to a mammalian subject.Type: ApplicationFiled: April 23, 2012Publication date: August 16, 2012Applicants: Baxter Healthcare S.A., Baxter International Inc.Inventors: James E. Kipp, Joseph Chung Tak Wong, Lakshmy Nair, Reagan Miller, Barrett E. Rabinow
-
Patent number: 8183233Abstract: Stable pharmaceutical formulations and methods of making same are provided. In a general embodiment, the present disclosure provides a method of making a stable pharmaceutical formulation comprising adding one or more vitrifying additives to an aqueous pharmaceutical solution to raise the glass transition temperature of the aqueous pharmaceutical solution. The aqueous pharmaceutical solution can be cooled to a temperature of about ?50° C. to about ?10° C. The vitrifying additive enhances the formation of a glass or amorphous solid of the aqueous pharmaceutical solution at cryogenic temperatures (?50 to ?10° C.), and the pharmaceutical formulation can be thawed to liquid form and administered to a mammalian subject.Type: GrantFiled: May 8, 2009Date of Patent: May 22, 2012Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: James E. Kipp, Joseph Chung Tak Wong, Lakshmy Nair, Reagan Miller, Barrett E. Rabinow
-
Publication number: 20100086611Abstract: The present invention relates to compositions of submicron- to micron-size particles of antimicrobial agents. More particularly the invention relates to a composition of an antimicrobial agent that renders the agent potent against organisms normally considered to be resistant to the agent. The composition comprises an aqueous suspension of submicron- to micron-size particles containing the agent coated with at least one surfactant selected from the group consisting of: ionic surfactants, non-ionic surfactants, biologically derived surfactants, and amino acids and their derivatives. The particles have a volume-weighted mean particle size of less than 5 ?m as measured by laser diffractometry.Type: ApplicationFiled: March 30, 2009Publication date: April 8, 2010Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.Inventors: Barrett Rabinow, Randy White, Chong-Son Sun, Joseph Chung Tak Wong, James E. Kipp, Mark J. Doty, Christine Rebbeck, Pavlos George Papadopoulos
-
Publication number: 20090286764Abstract: Stable pharmaceutical formulations and methods of making same are provided. In a general embodiment, the present disclosure provides a method of making a stable pharmaceutical formulation comprising adding one or more vitrifying additives to an aqueous pharmaceutical solution to raise the glass transition temperature of the aqueous pharmaceutical solution. The aqueous pharmaceutical solution can be cooled to a temperature of about ?50° C. to about ?10° C. The vitrifying additive enhances the formation of a glass or amorphous solid of the aqueous pharmaceutical solution at cryogenic temperatures (?50 to ?10° C.), and the pharmaceutical formulation can be thawed to liquid form and administered to a mammalian subject.Type: ApplicationFiled: May 8, 2009Publication date: November 19, 2009Applicants: Baxter International Inc., Baxter Healthcare S.A.Inventors: JAMES E. KIPP, JOSEPH CHUNG TAK WONG, LAKSHMY NAIR, REAGAN MILLER, BARRETT E. RABINOW
-
Publication number: 20090152176Abstract: The disclosure describes apparatuses and methods of use that may be used to remove material with magnetic properties from compositions, particularly pharmaceutical compositions. The apparatuses provide a conduit or column in which a magnetic field exists and through which a composition flows. Magnetic material in the composition is substantially reduced after flowing through the conduit or column.Type: ApplicationFiled: December 21, 2007Publication date: June 18, 2009Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.Inventors: James E. Kipp, Joseph Chung Tak Wong, Jane O. Werling
-
Patent number: 7511079Abstract: Methods and apparatuses for comminuting and stabilizing small particles are provided. In one embodiment, an apparatus moves an organic compound dissolved in a solvent to form a suspension of particles in a first fluid stream and moves the suspension in a second fluid stream, wherein the second fluid stream is oriented and positioned with respect to the first stream to cause shearing between the streams and mixing of at least some of the particles in the first and second streams.Type: GrantFiled: March 22, 2004Date of Patent: March 31, 2009Assignee: Baxter International Inc.Inventors: James E. Kipp, Joseph Chung Tak Wong, Monte Wisler, Rhonda Garcia
-
Patent number: 7193084Abstract: The present invention provides a polymorphic form of itraconazole.Type: GrantFiled: August 5, 2002Date of Patent: March 20, 2007Assignee: Baxter International Inc.Inventors: Jane Werling, Mark J. Doty, Christine L. Rebbeck, Joseph Chung Tak Wong, James E. Kipp
-
Patent number: 7177487Abstract: The present invention provides a method for determining a particle size.Type: GrantFiled: April 21, 2003Date of Patent: February 13, 2007Assignee: Baxter International Inc.Inventors: Damian Neuberger, Joseph Chung Tak Wong
-
Patent number: 7037528Abstract: The present invention provides a method for preparing submicron sized particles of an organic compound, the solubility of which is greater in a water-miscible first solvent than in a second solvent which is aqueous, the process including the steps of: (i) dissolving the organic compound in the water-miscible first solvent to form a solution, (ii) mixing the solution with the second solvent to define a pre-suspension; and (iii) adding energy to the pre-suspension to form particles having an average effective particle size of 400 nm to 2 microns.Type: GrantFiled: June 5, 2001Date of Patent: May 2, 2006Assignee: Baxter International Inc.Inventors: James E. Kipp, Joseph Chung Tak Wong, Mark J. Doty, Christine L. Rebbeck
-
Patent number: 7009169Abstract: The present invention provides for measuring a particle size distribution of a population of particles using a light scattering particle sizing instrument having a plurality of selectable imaginary component values of the refractive index. The particles each having a particle size and the process includes the steps of: (i) providing a population of the particles, wherein the particles have a refractive index; (ii) determining a real component of the refractive index of the particles using the Becke Line Method; (iii) determining an imaginary component of the refractive index of the particles; and (iv) determining the particle size distribution of the particles by the light scattering particle sizing instrument wherein the particle size distribution is determined using the real component of the refractive index measured in step (ii) and the imaginary component of the refractive index determined in step (iii).Type: GrantFiled: April 21, 2003Date of Patent: March 7, 2006Assignee: Baxter International Inc.Inventors: Joseph Chung Tak Wong, Damian Neuberger
-
Patent number: 6951656Abstract: The present invention provides a method for preparing submicron sized particles of an organic compound, the solubility of which is greater in a water-miscible first solvent than in a second solvent which is aqueous, the process including the steps of: (i) dissolving the organic compound in the water-miscible first solvent to form a solution, (ii) mixing the solution with the second solvent to define a pre-suspension; and (iii) adding energy to the pre-suspension to form particles having an average effective particle size of less than about 2 ?m.Type: GrantFiled: September 17, 2001Date of Patent: October 4, 2005Assignee: Baxter International Inc.Inventors: James E. Kipp, Joseph Chung Tak Wong, Mark J. Doty, Christine L. Rebbeck, Sean Brynjelsen
-
Patent number: 6884436Abstract: The present invention provides a method for preparing a suspension of a pharmaceutically-active compound, the solubility of which is greater in a water-miscible first organic solvent than in a second solvent which is aqueous. The process includes the steps of: (i) dissolving a first quantity of the pharmaceutically-active compound in the water-miscible first organic solvent to form a first solution; (ii) mixing the first solution with the second solvent to precipitate the pharmaceutically-active compound; and (iii) seeding the first solution or the second solvent or the pre-suspension.Type: GrantFiled: December 12, 2001Date of Patent: April 26, 2005Assignee: Baxter International Inc.Inventors: James E. Kipp, Joseph Chung Tak Wong, Mark J. Doty, Jane Werling, Christine L. Rebbeck, Sean Brynjelsen
-
Patent number: 6869617Abstract: The present invention provides a method for preparing submicron sized particles of an organic compound, the solubility of which is greater in a water-miscible first solvent than in a second solvent which is aqueous, the process including the steps of: (i) dissolving the organic compound in the water-miscible first solvent to form a solution, (ii) mixing the solution with the second solvent to define a pre-suspension; and (iii) adding energy to the pre-suspension to form particles having an average effective particle size of 400 nm to 2 microns.Type: GrantFiled: June 5, 2001Date of Patent: March 22, 2005Assignee: Baxter International Inc.Inventors: James E. Kipp, Joseph Chung Tak Wong, Mark J. Doty, Christine L. Rebbeck
-
Publication number: 20040266890Abstract: Methods and apparatuses for comminuting and stabilizing small particles are provided. In one embodiment, an apparatus moves an organic compound dissolved in a solvent to form a suspension of particles in a first fluid stream and moves the suspension in a second fluid stream, wherein the second fluid stream is oriented and positioned with respect to the first stream to cause shearing between the streams and mixing of at least some of the particles in the first and second streams.Type: ApplicationFiled: March 22, 2004Publication date: December 30, 2004Inventors: James E. Kipp, Joseph Chung Tak Wong, Monte Wisler, Rhonda Garcia
-
Publication number: 20040206890Abstract: The present invention provides for measuring a particle size distribution of a population of particles using a light scattering particle sizing instrument having a plurality of selectable imaginary component values of the refractive index. The particles each having a particle size and the process includes the steps of: (i) providing a population of the particles, wherein the particles have a refractive index; (ii) determining a real component of the refractive index of the particles using the Becke Line Method; (iii) determining an imaginary component of the refractive index of the particles; and (iv) determining the particle size distribution of the particles by the light scattering particle sizing instrument wherein the particle size distribution is determined using the real component of the refractive index measured in step (ii) and the imaginary component of the refractive index determined in step (iii).Type: ApplicationFiled: April 21, 2003Publication date: October 21, 2004Inventors: Joseph Chung Tak Wong, Damian Neuberger